曲美木单抗联合度伐利尤单抗治疗不可切除肝细胞癌的III期随机HIMALAYA研究亚洲亚组结局
HIMALAYA研究亚洲亚组(不包括日本)纳入479例不可切除肝细胞癌患者,随机接受STRIDE方案、度伐利尤单抗单药或索拉非尼治疗。STRIDE组总生存较索拉非尼组改善(HR 0.68,95%CI 0.52-0.89),度伐利尤单抗组与索拉非尼组总生存HR为0.83(95%CI 0.64-1.06)。
要点
- 亚洲亚组中STRIDE组总生存较索拉非尼组改善,HR 0.68(95%CI 0.52-0.89)。
- 度伐利尤单抗组与索拉非尼组总生存HR为0.83(95%CI 0.64-1.06)。
- 亚洲亚组中STRIDE组和度伐利尤单抗组客观缓解率数值上高于索拉非尼组,3/4级治疗相关不良事件数值上低于索拉非尼组。
核心结论
- 在亚洲亚组中,STRIDE方案较索拉非尼改善了结局,结果支持STRIDE在全球不可切除肝细胞癌患者中的获益,包括亚太地区。
研究设计与样本
- 全球III期随机HIMALAYA研究(NCT03298451)的亚洲亚组分析,纳入在香港、印度、韩国、台湾、泰国和越南入组的479例不可切除肝细胞癌参与者,随机分配至STRIDE组(n=156)、度伐利尤单抗组(n=167)或索拉非尼组(n=156)。
- 另对香港和台湾的探索性亚组(n=141)进行了分析。
主要发现
- 亚洲亚组中,STRIDE组较索拉非尼组总生存改善,HR 0.68(95%CI 0.52-0.89)。
- 亚洲亚组中,度伐利尤单抗组与索拉非尼组的总生存HR为0.83(95%CI 0.64-1.06)。
- 香港和台湾亚组(n=141)中,STRIDE组较索拉非尼组总生存HR为0.44(95%CI 0.26-0.77),度伐利尤单抗组与索拉非尼组总生存HR为0.64(95%CI 0.37-1.08)。
- 亚洲亚组中,客观缓解率(包括未确认的缓解)在STRIDE组为28.2%、度伐利尤单抗组为18.6%、索拉非尼组为9.0%,STRIDE组和度伐利尤单抗组数值上高于索拉非尼组。
- 亚洲亚组中,3/4级治疗相关不良事件在STRIDE组为19.9%、度伐利尤单抗组为13.3%、索拉非尼组为30.5%,STRIDE组和度伐利尤单抗组数值上低于索拉非尼组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In the global, phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) improved overall survival (OS) vs. sorafenib; durvalumab was non-inferior to sorafenib. HBV is the predominant HCC aetiology in most of Asia vs. HCV or non-viral aetiologies in Western countries and Japan. This analysis evaluated safety and efficacy outcomes for STRIDE and durvalumab monotherapy vs. sorafenib, in HIMALAYA participants enrolled in Asia, excluding Japan. METHODS: In HIMALAYA, participants were randomised to STRIDE, durvalumab, or sorafenib. The Asian subgroup in this analysis included participants enrolled in Hong Kong, India, South Korea, Taiwan, Thailand, and Vietnam. OS, objective response rate (ORR; per RECIST, version 1.1), and safety were assessed in the Asian subgroup and in an exploratory subgroup of participants in Hong Kong and Taiwan. RESULTS: The Asian subgroup included 479 participants randomised to STRIDE (n = 156), durvalumab (n = 167), or sorafenib (n = 156). OS was improved for STRIDE vs. sorafenib (hazard ratio [HR] 0.68; 95% CI 0.52-0.89). The OS HR for durvalumab vs. sorafenib was 0.83 (95% CI 0.64-1.06). In Hong Kong and Taiwan (n = 141), OS HRs for STRIDE vs. sorafenib and durvalumab vs. sorafenib were 0.44 (95% CI 0.26-0.77) and 0.64 (95% CI 0.37-1.08), respectively. In the Asian subgroup, ORR (including unconfirmed responses) was numerically higher for STRIDE (28.2%) and durvalumab (18.6%) vs. sorafenib (9.0%), and Grade 3/4 treatment-related adverse events were numerically lower for STRIDE (19.9%) and durvalumab (13.3%) vs. sorafenib (30.5%). CONCLUSIONS: STRIDE improved outcomes vs. sorafenib in the Asian subgroup. These results support the benefits of STRIDE for participants with uHCC globally, including in the Asia-Pacific region. CLINICAL TRIAL NUMBER: NCT03298451. IMPACT AND IMPLICATIONS: The global, phase III HIMALAYA study found that the STRIDE (Single Tremelimumab Regular Interval Durvalumab) regimen improved overall survival (OS), including long-term OS vs. sorafenib, and that durvalumab monotherapy was non-inferior to sorafenib in participants with unresectable hepatocellular carcinoma (uHCC). However, there are differences in the aetiology and clinical practices related to HCC in parts of Asia, compared to Western countries and Japan, which could lead to differences in treatment outcomes between these regions. The results of this analysis demonstrate the benefits of STRIDE for participants in the Asia-Pacific region, consistent with the full, global study population. Overall, these findings continue to support the use of STRIDE in a diverse population, reflective of uHCC globally.
引用
- Lau G, Abou-Alfa GK, Cheng AL, et al. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. J Hepatol. 2024. PMID: 39089633. doi:10.1016/j.jhep.2024.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。